Biograil™ has raised $22.4M in a round backed by Verve Ventures, Megatrend Invest, and HTGF. The pre-clinical stage pharmaceutical company is developing its proprietary BIONDD™ technology, which aims to turn injectable pharmaceutical products into convenient oral capsules.












